Breast cancer-related lymphedema treament with negative pressure device
1 in 5 women develop lymphedema (LE) following breast cancer (BC) treatment. If untreated, LE may become chronic and result in persistent swelling, inflammation, skin thickening, and abnormal fibro-adipose tissue deposition. Current conservative treatments do not specifically address secondary soft tissue changes that may limit response to treatment. The purpose of this pilot randomized controlled trial (RCT) is to evaluate efficacy of treatment for chronic LE using a negative-pressure device, which mobilizes skin and subcutaneous tissue to support lymphatic circulation.